Q4 EPS Estimates for AngioDynamics Lowered by HC Wainwright

AngioDynamics, Inc. (NASDAQ:ANGO) – Investment analysts at HC Wainwright lowered their Q4 2027 earnings per share estimates for shares of AngioDynamics in a research report issued to clients and investors on Wednesday, July 15th. HC Wainwright analyst Y. Chen now forecasts that the medical instruments supplier will post earnings per share of $0.01 for the quarter, down from their prior forecast of $0.05. HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.26) per share.

Several other analysts also recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. Canaccord Genuity Group raised their price objective on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Finally, Zacks Research cut shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $19.50.

AngioDynamics Trading Up 11.3%

Shares of ANGO opened at $14.47 on Thursday. The firm has a market cap of $597.89 million, a PE ratio of -16.63 and a beta of 0.34. The company’s 50 day simple moving average is $12.14 and its 200-day simple moving average is $11.33. AngioDynamics has a 12-month low of $8.36 and a 12-month high of $14.80.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The company had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS.

Institutional Investors Weigh In On AngioDynamics

Several large investors have recently modified their holdings of the stock. Farther Finance Advisors LLC grew its position in AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 1,199 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new position in AngioDynamics during the 4th quarter worth $27,000. State of Wyoming purchased a new position in AngioDynamics during the 2nd quarter worth $31,000. Russell Investments Group Ltd. lifted its stake in shares of AngioDynamics by 329.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 3,213 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in shares of AngioDynamics by 359.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 4,268 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Key Headlines Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics reported Q4 adjusted EPS of -$0.07, better than the -$0.11 estimate, while revenue of $86.61 million also topped forecasts. Article Title
• Positive Sentiment: Management said fiscal 2026 was a record year, with continued execution driving Med Tech growth and full-year profitability, which can support a stronger investor narrative. Article Title
• Positive Sentiment: AngioDynamics raised its fiscal 2027 revenue outlook to $336 million-$341 million, above consensus, signaling confidence in continued top-line growth. Article Title
• Positive Sentiment: HC Wainwright increased its price target on ANGO from $16 to $19 and reiterated a buy rating, implying further upside if execution continues. Article Title
• Neutral Sentiment: Analysts now broadly expect AngioDynamics to keep improving, but profitability remains negative and the company’s FY2027 EPS guidance is still below consensus, so investors may want to watch whether margin gains continue.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.